A phase II multicenter study of stereotactic radiotherapy (SRT) for oligoprogression in metastatic renal cell cancer (mRCC) patients receiving tyrosine kinase inhibitor (TKI) therapy.
Patrick Cheung(Sunnybrook Health Science Centre), Georg A. Bjarnason(Sunnybrook Health Science Centre), Arjun Sahgal(Sunnybrook Health Science Centre), Scott C. Morgan(University of Ottawa), Tamim Niazi(Jewish General Hospital), Samir Patel(University of Alberta), François Patenaude(Jewish General Hospital), Eric Winquist(Western University), Hany Soliman(Sunnybrook Health Science Centre), Scott North, Piotr Czaykowski(CancerCare Manitoba), Sareh Keshavarzi(University of Toronto), William Chu(Sunnybrook Health Science Centre), Belal Ahmad(London Health Sciences Centre), Arbind Dubey(CancerCare Manitoba), Justin White(Ozmosis Research (Canada)), Rebecca Wong(Princess Margaret Cancer Centre), Daniel Yick Chin Heng(University of Calgary), Anand Swaminath(Juravinski Cancer Centre)
Cited by 9
Related Papers
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2012|1.4k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
|Journal of Clinical Oncology|2020|1.3k